ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · Eur J Heart Fail · 2026-09-15

Post hoc analysis of 1648 HFpEF patients in TOPCAT Americas: an early eGFR dip (≥15% by week 4) was more common with spironolactone than placebo (33% vs 20%) and was associated with worse outcomes, but spironolactone's effect did not differ by dip (P interaction .81).

Secondary analysisn = 1,648
Beldhuis et al. Spironolactone, early acute eGFR changes, and clinical outcomes in patients with heart failure with preserved ejection fraction: insights from TOPCAT Americas
Cardiology · Eur J Heart Fail · 2026-09-15

Bayesian network meta-analysis of 8 RCTs (10 644 patients with HFpEF/HFmrEF): only finerenone reduced HF hospitalisation vs placebo (RR 0.84); spironolactone and eplerenone were non-significant; no MRA reduced CV death; finerenone and spironolactone increased hyperkalaemia.

Meta-analysisn = 10,644
Bagattoli et al. Finerenone, eplerenone, and spironolactone in heart failure with preserved ejection fraction: a Bayesian network meta-analysis of efficacy and safety

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.